Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

  • ID: 4436056
  • Report
  • 2678 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • BeiGene Ltd
  • DEKK-TEC Inc
  • Golden Biotechnology Corp
  • Kyowa Hakko Kirin Co Ltd
  • Onxeo SA
  • MORE
Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 47, 206, 192, 18, 167, 19 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 45 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • BeiGene Ltd
  • DEKK-TEC Inc
  • Golden Biotechnology Corp
  • Kyowa Hakko Kirin Co Ltd
  • Onxeo SA
  • MORE
Introduction

Non-Small Cell Lung Cancer - Overview

Non-Small Cell Lung Cancer - Therapeutics Development

Non-Small Cell Lung Cancer - Therapeutics Assessment

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development

Non-Small Cell Lung Cancer - Drug Profiles

Non-Small Cell Lung Cancer - Dormant Projects

Non-Small Cell Lung Cancer - Discontinued Products

Non-Small Cell Lung Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cadila Healthcare Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cell Medica Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cortice Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017

Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Dynavax Technologies Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by eFFECTOR Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Co, H2 2017

Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Enzene Biosciences Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by EpiThany Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Epizyme Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by F-star Biotechnology Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Formosa Laboratories Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Fountain Biopharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Fujifilm Holdings Corporation, H2 2017

Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Galectin Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Immatics Biotechnologies GmbH, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Imugene Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Incyte Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Inflection Biosciences Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Innovent Biologics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Invectys SA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Inventiva, H2 2017

Non-Small Cell Lung Cancer - Pipeline by IO Biotech ApS, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Io Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by JHL Biotech Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Jounce Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Juno Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Kadmon Corp LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Kite Pharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Kura Oncology Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Leap Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Lidds AB, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Loxo Oncology Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Luye Pharma Group Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Lycera Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by MacroGenics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Non-Small Cell Lung Cancer - Pipeline by MallInckrodt Plc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Merus NV, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Microlin Bio Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Molecular Partners AG, H2 2017

Non-Small Cell Lung Cancer - Pipeline by MolMed SpA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Morphotek Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Multimmune GmbH, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Mundipharma International Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Mycenax Biotech Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by NantKwest Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Neumedicines Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Oncobiologics Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Oncolys BioPharma Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Onxeo SA, H2 2017

Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics LLC, H2 2017

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • 3SBio Inc
  • 4SC AG
  • AbbVie Inc
  • Ability Pharmaceuticals SL
  • ACEA Biosciences Inc
  • Adamed Sp z oo
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics Sarl
  • Aduro BioTech Inc
  • Advantagene Inc
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Agenus Inc
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Altimmune Inc
  • Altor BioScience Corp
  • Amgen Inc
  • Andarix Pharmaceuticals Inc
  • AndroScience Corp
  • Apexigen Inc
  • Aptose Biosciences Inc
  • Argos Therapeutics Inc
  • Ariad Pharmaceuticals Inc
  • ARMO Biosciences Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Ascentage Pharma Group Corp Ltd
  • Astellas Pharma Inc
  • Asterias Biotherapeutics Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atreca Inc
  • Aurigene Discovery Technologies Ltd
  • Aurobindo Pharma Ltd
  • AVEO Pharmaceuticals Inc
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • BerGenBio ASA
  • Beta Pharma Inc
  • Betta Pharmaceuticals Co Ltd
  • BeyondSpring Pharmaceuticals Inc
  • Bicycle Therapeutics Ltd
  • Bio-Cancer Treatment International Ltd
  • Biocad
  • BioCancell Ltd
  • Biocon Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioLineRx Ltd
  • Bionovis SA
  • Biothera Pharmaceutical Inc
  • Blueprint Medicines Corp
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • BrightPath Biotherapeutics Co Ltd
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • Cantargia AB
  • Cascadian Therapeutics Inc
  • CASI Pharmaceuticals Inc
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellmid Ltd
  • Cellular Biomedicine Group Inc
  • Checkpoint Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Chugai Pharmaceutical Co Ltd
  • Cielo Therapeutics Inc
  • Cleave Biosciences Inc
  • Cleveland BioLabs Inc
  • Coherus BioSciences Inc
  • Corcept Therapeutics Inc
  • Cortice Biosciences Inc
  • Corvus Pharmaceuticals Inc
  • Critical Outcome Technologies Inc
  • CSPC Pharmaceutical Group Limited
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • DAE HWA Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • DanDrit Biotech A/S
  • Debiopharm International SA
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Denovo Biopharma LLC
  • Domainex Ltd
  • Double Bond Pharmaceutical International AB
  • Dr. Reddy's Laboratories Ltd
  • Dynavax Technologies Corp
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • Eli Lilly and Co
  • EnGeneIC Ltd
  • EntreChem SL
  • Enumeral Biomedical Holdings Inc
  • Enzene Biosciences Ltd
  • EpiThany Inc
  • Epizyme Inc
  • Eudendron Srl
  • Evotec AG
  • Exelixis Inc
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroStatin SL
  • Five Prime Therapeutics Inc
  • Formosa Laboratories Inc
  • Fountain Biopharma Inc
  • Fujifilm Holdings Corporation
  • G&E Herbal Biotechnology Co Ltd
  • G1 Therapeutics Inc
  • Galectin Therapeutics Inc
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Genmab A/S
  • Genocea Biosciences Inc
  • Genor BioPharma Co Ltd
  • Genosco Inc
  • Genzyme Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GlycaNova Norway AS
  • Glycotope GmbH
  • Golden Biotechnology Corp
  • Gradalis Inc
  • Grunenthal GmbH
  • Halozyme Therapeutics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Heat Biologics Inc
  • Helix BioPharma Corp
  • Hemispherx Biopharma Inc
  • Heptares Therapeutics Ltd
  • HitGen LTD
  • Horizon Pharma Plc
  • Hutchison MediPharma Ltd
  • iCeutica Inc
  • Ideaya Biosciences Inc
  • Ignyta Inc
  • Immatics Biotechnologies GmbH
  • Immune Design Corp
  • Immune Pharmaceuticals Inc
  • ImmunGene Inc
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Imugene Ltd
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Inflection Biosciences Ltd
  • Innovation Pharmaceuticals Inc
  • Innovent Biologics Inc
  • Inovio Pharmaceuticals Inc
  • Invectys SA
  • Inventiva
  • IO Biotech ApS
  • Io Therapeutics Inc
  • Iovance Biotherapeutics Inc
  • JHL Biotech Inc
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • Juno Therapeutics Inc
  • Kadmon Corp LLC
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • Kura Oncology Inc
  • Kyowa Hakko Kirin Co Ltd
  • Laboratoires Pierre Fabre SA
  • LATITUDE Pharmaceuticals Inc
  • Leap Therapeutics Inc
  • Les Laboratoires Servier SAS
  • Lidds AB
  • Loxo Oncology Inc
  • Luye Pharma Group Ltd
  • Lycera Corp
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc.
  • MallInckrodt Plc
  • Mebiopharm Co Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Merus NV
  • Microlin Bio Inc
  • Millennium Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Moderna Therapeutics Inc
  • Molecular Partners AG
  • MolMed SpA
  • Morphotek Inc
  • Multimmune GmbH
  • Mundipharma International Ltd
  • Mycenax Biotech Inc
  • NanoCarrier Co Ltd
  • NantKwest Inc
  • Natco Pharma Ltd
  • Nektar Therapeutics
  • Neumedicines Inc
  • NewLink Genetics Corp
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Oncobiologics Inc
  • Oncolys BioPharma Inc
  • Oncolytics Biotech Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Optimum Therapeutics LLC
  • OSE Immunotherapeutics
  • Paranta Biosciences Ltd
  • Peptomyc SL
  • Peregrine Pharmaceuticals Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • Phosplatin Therapeutics LLC
  • Pique Therapeutics
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Provectus Biopharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • Puma Biotechnology Inc
  • Purdue Pharma LP
  • Qilu Pharmaceutical Co Ltd
  • Qu Biologics Inc
  • Qurient Co Ltd
  • Rafael Pharmaceuticals Inc
  • RaQualia Pharma Inc
  • Reata Pharmaceuticals Inc
  • Recombio SL
  • Regeneron Pharmaceuticals Inc
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • RS Research
  • Samyang Holdings Corp
  • Sanofi
  • Scancell Holdings Plc
  • SciClone Pharmaceuticals Inc
  • ScinoPharm Taiwan Ltd
  • Seattle Genetics Inc
  • Selvita SA
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Shanghai Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Sierra Oncology Inc
  • Sigma-Tau SpA
  • SignPath Pharma Inc
  • Simcere Pharmaceutical Group
  • Sino Biopharmaceutical Ltd
  • Sotio AS
  • Spotlight Innovation Inc
  • Starpharma Holdings Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • SuviCa Inc
  • Symphogen A/S
  • Synactix Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Synermore Biologics Co Ltd
  • Systimmune Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll